Verrica climbs after Japan's nod for skin infection drug

** Shares of Verrica Pharmaceuticals VRCA rise 18% to $4.78 premarket

** Company says its partner Torii Pharmaceutical has received approval in Japan for their skin infection drug, Ycanth

** The drug gets Japan's nod for the treatment of molluscum contagiosum — a common viral skin infection that causes small, raised bumps and spreads through direct contact with infected skin or contaminated objects

** The approval triggers a $10 million milestone payment to Verrica

** Ycanth is already approved by the U.S. FDA to treat the condition in adult and pediatric patients two years of age and older

** As of last close, shares down 42% YTD